By Cian Muenster and Bartosz Dabrowski
Feb 18 (Reuters) – Straumann forecast 2026 sales growth in a high single-digit percentage after last year’s revenue beat market expectations on Wednesday, as the dental implant maker awaits the next round of China’s volume-based procurement (VBP).
Shares of the Swiss group rose up to 6% in early trading and were 1.6% higher by 0855 GMT, with analysts highlighting strong fourth-quarter sales alongside the reassuring outlook.
Implant prices for end-customers have fallen sharply under China’s new volume-based procurement model, boosting demand in the country.
However, Straumann said demand in China was softer ahead of the next procurement round, which was postponed from December until a yet unannounced date. Analysts from Jefferies said companies in the sector have alluded to the second quarter of 2026 as the new timing.
“We have not received detailed information on the next round of the China VBP,” CEO Guillaume Daniellot told Reuters in an interview. “There have been some early indications and market discussions that the locally manufactured products would be favoured in the next VBP round,” he added.
Daniellot had told investors during Straumann’s earlier capital markets day that no strong local challenger had emerged in China.
“We have really organized ourselves to be able to have all the different options for us to be able to play the new VBP rules in the best manner,” he said on Wednesday.
Outside of China, the company flagged a solid performance in Europe, North America and the Asia-Pacific regions.
In 2025, its revenue grew to 2.61 billion Swiss francs ($3.4 billion), above analysts’ average estimate of 2.59 billion francs in a Vara consensus. Annual organic sales growth of 8.9% was also slightly above expectations.
($1 = 0.7707 Swiss francs)
(Reporting by Cian Muenster and Bartosz Dabrowski in Gdansk; Editing by Matt Scuffham and Milla Nissi-Prussak)
Comments